Meeting
2022 ASCO Annual Meeting
Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Authors
Alexander E. Drilon
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Alexander E. Drilon , Jessica Jiyeong Lin , Shivaani Kummar , Daniel Shao-Weng Tan , Jyoti D. Patel , Ulrik Niels Lassen , Serge Leyvraz , Victor Moreno , Lee S. Rosen , Benjamin Maurice Solomon , Jeffrey Yachnin , Yongmei Liu , Ming-Shen Dai , Ricarda Norenberg , Marc Mardoche Fellous , Chiara Erminia Mussi , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02576431, NCT02122913
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9024)
DOI
10.1200/JCO.2022.40.16_suppl.9024
Abstract #
9024
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
First Author: Jessica Jiyeong Lin
Poster
2024 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.
First Author: Alexander E. Drilon
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong
Poster
2023 ASCO Annual Meeting
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
First Author: Maria E. Cabanillas